• HyperScribe T7 Cy5 RNA Labeling: Documented Scope

  2026-10-15

  The HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit is described by APExBIO as a research-use kit for producing fluorescent RNA probes through T7 RNA polymerase-mediated in vitro transcription with Cy5-UTP. Its documented scope includes in situ hybridization and Northern blot hybridization probe preparation, but the available product information does not provide identity-matched independent performance data, quantitative labeling metrics, comparative studies, or application-specific validation.

• What the Record Establishes About Recombinant Mouse CD4

  2026-10-15

  The available record supports only a catalog-level identity claim for APExBIO’s Recombinant Mouse CD4, Tag Free (SKU P2012). It does not provide a matched research study, mechanistic characterization, assay readout, performance comparison, or outcome statistics. Accordingly, the product name can define the intended molecular category, but it cannot establish biological activity, assay suitability, or comparative value.

• CD36, Lipid Signaling, and Immune Escape in AML

  2026-10-14

  The 2024 Cell Reports Medicine study presents CD36 as more than a fatty-acid transporter in acute myeloid leukemia: it functions as a tumor-cell signaling receptor that integrates oxidized LDL and palmitate inputs to activate TLR4–MYD88–NF-κB signaling and suppress antitumor T-cell activity. Genetic, pharmacologic, immunologic, and mouse-model evidence supports this mechanism, while the study’s preclinical design, limited patient sampling, lineage dependence, and unexamined roles of CD36 on immune cells constrain transferability. The findings are mechanistically distinct from the arginase-focused evidence associated with nor-NOHA acetate.

• Entecavir: Evidence, Mechanism and Boundaries

  2026-10-14

  Entecavir is a potent HBV DNA polymerase inhibitor with a high genetic barrier to resistance. The supplied evidence supports its conceptual relevance to chronic hepatitis B infection therapy, including decompensated liver disease, while leaving important limits around study age, population heterogeneity, surrogate endpoints and generalization from models to patients.

• nor-NOHA: Evidence Boundaries Across Cancer Models

  2026-10-13

  nor-NOHA acetate is described as a reversible arginase inhibitor, but the supplied evidence comes from specific liver-enzyme, HepG2, and rat vascular models. A separate AML study identifies a CD36-dependent lipid–immune pathway without testing nor-NOHA, so any connection between arginase inhibition and AML immune escape remains unestablished.

• ZNF263, STAT3 and Colorectal Cancer Resistance

  2026-10-13

  A 2024 Scientific Reports study links elevated ZNF263 with colorectal cancer progression and reports STAT3 as a molecular mediator of malignant cell behavior and chemoradiotherapy resistance. The findings are mechanistically suggestive but remain primarily preclinical and do not establish clinical utility or treatment benefit.

• COMET and the Challenge of LNP Design

  2026-10-12

  A source-grounded overview of a Nature Nanotechnology study introducing COMET, a transformer-based model designed to represent complete lipid nanoparticle formulations rather than individual lipids alone. The study reports promising predictive and validation results, while leaving important questions about dataset bias, broader generalizability, biological safety and clinical translation.

• nor-NOHA: Evidence, Mechanism and Boundaries

  2026-10-12

  A source-grounded overview of nor-NOHA acetate as a reversible arginase inhibitor, separating supplier-reported cancer and vascular findings from the distinct CD36-mediated immune-metabolism findings reported in AML.

• Dimetridazole MIP Sensor: Findings and Limits

  2026-10-10

  The 2020 Analytica Chimica Acta study developed a poly-arginine molecularly imprinted polymer sensor for selective electrochemical detection of Dimetridazole, also known as 1,2-Dimethyl-5-nitroimidazole. Its reported 0.1 nM detection limit and application to egg, milk, and honey demonstrate strong analytical potential, while the study design remains focused on residue measurement rather than antimicrobial or therapeutic activity.

• Dextran Sulfate Sodium Salt in Colitis Research

  2026-10-09

  Dextran sulfate sodium salt, including DSS (MW 35000-45000), is widely used as a chemical injury model for studying intestinal inflammation and mucosal repair. This overview separates supplier descriptions from peer-reviewed evidence, examines how DSS can frame questions about epithelial barrier failure, and discusses a 2026 Cell Death & Disease study reporting a GPR35-KLF5 repair circuit linked to tryptophan metabolism. It also defines the model’s boundaries: chemical epithelial injury is not equivalent to human ulcerative colitis, and mechanistic findings require independent replication and quantitative validation.

• Romidepsin (FK228): HDAC Biology & HCC Evidence

  2026-10-09

  Romidepsin, also called FK228, is a class I HDAC inhibitor used to study epigenetic modulation, cell-cycle arrest, and apoptosis. Recent hepatocellular carcinoma research links HDAC2-dependent SmD2 regulation to alternative splicing and PARP-inhibitor sensitivity, but the combination evidence remains preclinical.

• CD36 Lipid Signaling and Immune Escape in AML

  2026-10-08

  Guo et al. show that CD36 supports acute myeloid leukemia immune escape through a non-canonical lipid-sensing pathway in which oxidized LDL and palmitate jointly activate innate immune signaling, rather than simply fueling lipid oxidation. The study also reports that high-fat conditions and decitabine can intensify this immunosuppressive program, while statin-mediated pathway targeting improved decitabine responses in the reported models.

• Cleavage-Resistant TREM2 and Macrophage Efferocytosis

  2026-10-08

  Dong et al. engineered a cleavage-resistant TREM2 receptor that preserves DAP12-linked signaling when inflammatory ADAM17 activity would otherwise impair macrophage efferocytosis. In mouse models of metabolic-dysfunction-associated steatohepatitis and atherosclerosis, phosphatidylserine-functionalized lipid nanoparticles delivered CRT mRNA in situ and reduced apoptotic-cell accumulation and inflammation, while leaving important translational questions unresolved.

• Central Opioid Control of Mechanical Hypersensitivity

  2026-10-07

  Yin et al. (2024) identify a lateral parabrachial-to-hypothalamic-to-spinal circuit that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study separates mechanical pain outcomes from better-established thermal effects and provides convergent circuit evidence for spinal gate-control disruption as a central mechanism.

• Partial BACE1 Inhibition and Synaptic Transmission

  2026-10-07

  Satir and colleagues examined whether partial BACE inhibition could reduce amyloid-beta secretion without impairing synaptic transmission. In cultured rat cortical neurons, reductions below 50% were not associated with detectable synaptic dysfunction, whereas stronger inhibition reduced both amyloid-beta secretion and synaptic transmission, supporting a cautious exposure-response interpretation rather than a simple all-or-none model.

7392 records 1/493 page Next 12345 下5页 Last page